PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 3, 2026Journal of Oral Biology and Craniofacial Research0 citationsOpen Access

High UBE2D1 expression is associated with poor prognosis and immunotherapy resistance in head and neck cancer

View Full Paper
PPPrathibha PrasadPAParamasivam Arumugam

Key Points

  • Poor prognosis is linked to high levels of UBE2D1 expression in head and neck squamous cell carcinoma.
  • UBE2D1 is frequently overexpressed, correlating with adverse clinical outcomes in the disease.
  • Results imply that UBE2D1 may serve as a prognostic biomarker for patient management in HNSCC.
  • Further validation is needed to confirm UBE2D1's role in predicting immunotherapy response.

Abstract

UBE2D1 is frequently overexpressed in HNSCC and is associated with adverse clinical outcomes. Although its association with immunotherapy response requires further validation, UBE2D1 may be a prognostic biomarker in HNSCC.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Prasad et al. (2026) studied this question.

synapsesocial.com/papers/69a76125c6e9836116a2ecd3https://doi.org/10.1016/j.jobcr.2026.101423
Ask AI
Helpful
Bookmark
Share
View Full Paper